Development of a drug form gelable on the skin surface for the treatment of radiodermatitis
A thermosensitive gel formulation with dexketoprofen trometamol and lidocaine nanosuspension addresses the lack of effective treatments for radiodermatitis by offering sustained anti-inflammatory and analgesic effects, ensuring continuous radiotherapy and improved patient quality of life.
Patent Information
- Application Number
- PCT/TR2024/050460
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Filing Date
- 2024-05-09
- Publication Date
- 2024-12-05
AI Technical Summary
Current treatments for radiodermatitis are inadequate, with no specific standard therapy available, leading to interruptions in radiotherapy due to painful skin symptoms and lack of effective products for managing inflammation and pain.
A thermosensitive gel formulation containing a dexketoprofen trometamol and lidocaine nanosuspension, stabilized with poloxamer, which is easily applied topically, instantly gels on the skin, and provides sustained anti-inflammatory and local anesthetic effects, minimizing symptoms without requiring direct contact with the damaged area.
The formulation effectively reduces pain and inflammation, allowing continuous radiotherapy by providing a sprayable, easy-to-apply product that maintains active substance accumulation in the skin, thereby improving patient quality of life and treatment continuity.
Smart Images

Figure IMGF000008_0001 
Figure IMGF000008_0002 
Figure IMGF000008_0003
Abstract
Description
[0001] DEVELOPMENT OF A DRUG FORM GELABLE ON THE SKIN SURFACE FOR THE TREATMENT OF RADIODERMATITIS
[0002] Technical Field
[0003] It concerns the formulation of a thermosensitive gel containing dexketoprofen trometamol and lidocaine nanosuspension.
[0004] State of the art
[0005] Radiodermatitis is a disorder that affects the quality of life of patients and for which there is no specific treatment protocol. It has been reported that 95% of patients undergoing radiotherapy develop radiodermatitis, which is characterized by skin changes such as dermatitis, erythema and ulceration. This percentage is very high, and these symptoms may cause the treatment to be ceased for a while. Since continuity of treatment is important, radiodermatitis needs to be treated.
[0006] In the application for EP2494973 A1 (GUGLIELMINI G.), a topical preparation was disclosed for the treatment of radiodermatitis that contains vitamin C or derivatives thereof, a combination of plant extracts with Echinacea angustifolia extract and high triterpene saponin content as well as a lipophilic matrix including lecithin, trehalose and ceramides; polyphenols obtained from oat extract; a sunscreen; and a film-forming polymer.
[0007] CN104666528 A (Zu) concerns an emulsified paste containing herbal drugs for the treatment of radiodermatitis.
[0008] CN 105596600 A (Chengdu) concerns a plaster containing herbal drugs for the treatment of radiodermatitis.
[0009] CN101254203 A (Huanchen) concerns a solution containing polyriboinosinic - polyribocytidylic acid, vitamin A and oryzanol for the treatment of radiodermatitis.
[0010] CN107595873 B (Song) concerns the transdermal administration of a preparation containing metformin hydrochloride and uridine triacetate for the treatment of radiodermatitis.
[0011] CN107115271 A (He Jie) concerns a gel containing topical anesthetic, glucocorticoid, androgen for the treatment of radiodermatitis. WO201 1017195 A2 (Wang) concerns topical compositions in the form of cream, gel, lotion or transdermal pet containing nanoparticles suspension of various active substances. Lidocaine and dexketoprofen are specified among the compounds. Treatment of dermatitis is not specified.
[0012] US2022202825 A1 (Zalzal) concerns a transdermal cream containing ketoprofen and lidocaine as well as cephalexin or clindamycin for the treatment of cellulitis.
[0013] Currently, there is no well-established standard therapy for the prevention and treatment of radiodermatitis. It is reported that relief adverse symptoms depend on clinicians' ability to accurately assess the risk of developing radiodermatitis and predict the extent of skin damage. Today, there are no products specifically for the treatment of radiodermatitis. Depending on the severity of the radiodermatitis, the physician may recommend to the patient some dermatologic preparations that have no direct indication of radiodermatitis. Therefore, it is required to develop an effective and safe formulation for the treatment of radiodermatitis.
[0014] Brief description of the invention
[0015] The main purpose of our invention is to ensure that the treatment of patients receiving radiotherapy continues without interruption. For this purpose, a gel system with antiinflammatory and local anesthetic effect has been developed which can be easily used dermally in cases of radiodermatitis, that can be easily sprayed since it is liquid at room temperature, that is instantly gelable on the skin surface to cover the damaged skin surface and that can minimize the symptoms of radiodermatitis. The developed formulation can be used in the treatment of radiodermatitis due to the positive effect of the active substances it comprises, as well as the ease of use and instant gelling feature on the skin.
[0016] In cases of radiodermatitis, it is reported that a painful sensation occurs on the skin based on the degree of damage to the skin. In the product subject to invention developed for these patients, lidocaine is used as a local anesthetic along with dexketoprofen trometamol.
[0017] A gel formulation was developed in the form of nanosuspension comprising dexketoprofen Trometamol and lidocaine. It is known that nanosuspensions have a positive effect on the bioavailability of dermally administered active substances, that can better penetrate the skin, that provide a sustained effect, especially by increasing the accumulation of active substance in the skin, and that they can also reduce drug transfer to the systemic circulation. In our invention, we benefited from these advantages of lidocaine nanosuspension. In addition, the preparation can be applied with minimal pain without touching the radiodermatitis area since the developed gel formulation has thermosensitive characteristic. After the application, the formulation will remain on the skin longer by getting gelled on the skin and it will act for a long time.
[0018] Detailed description of the invention
[0019] In our invention, dexketoprofen trometamol, a non-steroidal anti-inflammatory agent, was used as an active ingredient to relieve the local inflammatory response, which is the main symptom of radiodermatitis. Poloxamer 407 was used as polymer while developing the thermosensitive gel system. Chitosan, hyaluronic acid and sodium polyacrylate together with poloxamer were tried to be used and it was decided to use poloxamer and chitosan together. Then, the final product was obtained by adding optimum lidocaine nanosuspension formulation wherein poloxamer was used as a stabilizer was added to the thermosensitive gel system comprising dexketoprofen trometamol and it was ensured that the formulation would accumulate especially in the stratum corneum and the local anesthetic effect of the same would be maintained for a long time.
[0020] Lidocaine base or any salt of the same is used for lidocaine nanosuspension. In the patent, lidocaine refers to the base and any salt thereof. As for the preparation of nanosuspensions, stabilizers commonly used to stabilize include polymers (e.g. Polyvinyl prolidone (PVP), hydroxypropylmethylcellulose (HPMC), hydroxypropylcellulose (HPC), polyethylene glycols (PEG), D-a-tocopherol polyethyleneglycol 1000 succinate (TPGS 1000), polyvinyl alcohols (PVA), amphiphilic amino acid copolymers, crystalline cellulose), ionic surfactants (e.g, sodium dodecyl sulfate (SDS), sodium lauryl sulfate (SLS), poly(ethylene imine) (PEI), chitosan) and non-ionic surfactants (e.g. Tweenes and poly(ethylene oxide)- polypropylene oxide) (PEO-PPO-PEO) block copolymers). In addition to these commonly used stabilizers, food proteins such as soybean protein isolate, whey protein isolate and [3-lactoglobulin have also been reported to be used as stabilizers in nanosuspension formulations. While ionic surfactants stabilize suspensions through electrostatic repulsion, polymers and non-ionic surfactants facilitate suspension stability through steric repulsion. As part of the study, polyvinylalcohol and poloxamer were tested as stabilizers while developing the nanosuspension formulation. Nanosuspensions prepared with different stabilizers were obtained and their characteristic properties were determined by performing all controls. As a result of the characterization studies, poloxamer was selected as the most suitable stabilizer. Lidocaine nanosuspension comprises 2-10% lidocaine base and 0.2-5% poloxamer by weight.
[0021] Ball milling, one of the different techniques used in the preparation of nanosuspensions, is an easy, scale-up-allowing and highly reproducible method compared to nanoparticle production. In this technique, a rough suspension of the drug substance is placed in a mill comprising a stabilizing agent, small, hard beads. Thanks to mechanical abrasion of the drug particles with the grinding media, nanosuspensions can be produced in the desired size range. By applying a quality by design (QbD) approach to nanosuspension preparation, critical process and formulation parameters were identified and optimized in the production stages. The final formulation was obtained by adding the optimum nanosuspension prepared and dexketoprofen trometamol into the thermosensitive gel system.
[0022] Characterization studies and stability studies were carried out in Lidocaine nanosuspension formulations prepared with different stabilizers. In addition, characterization studies and stability studies were carried out in gel formulations comprising lidocaine nanosuspension and dexketoprofen trometamol.
[0023] The final gel formulation comprises Lidocaine nanosuspension that is equivalent to 2-10 % by weight, 1.5 - 2 %, preferably; 1.85% dexketoprofen trometamol by weight, 14-20% Poloxamer by weight and 0.0625-1 % Chitosan by weight. Distilled water used in gel formulation comprises 0.5% acetic acid by volume.
[0024] While developing the nanosuspension formulation of base lidocaine in nanosize, different stabilizing polymers were tried. Polyvinyl alcohol (different molecular weights) and poloxamer (different types) were used separately to provide physical stabilization and nanosuspensions prepared with different stabilizers were obtained and their characteristic properties were determined by performing all controls. It was determined that the nanosuspensions prepared with poloxamer we chose were suitable for our purpose as a result of in vitro release studies, ex-vivo skin permeation studies and stability studies in particular, and they were added to the thermosensitive gel system.
[0025] While developing the thermosensitive gel system, once again a poloxamer type selected by us was used as a thermosensitive polymer. Poloxamers can be used as both physical stabilizers and thermosensitive gel forming polymers in such systems. In addition to poloxamers, different polymers that show heat-sensitive gelation properties can also be used. In addition to the heat-sensitive gel-forming poloxamer, a different polymer was added to the gel system to reduce / elim inate the skin damage in case of radiodermatitis. For this purpose, chitosan selected by us, hyaluronic acid with appropriate molecular size and sodium polyacrylate were used. Chitosan was selected as the most suitable polymer as a result of gelation time, gelation temperature, viscosity determination, texture profile analysis, in vitro release and ex vivo permeation studies.
[0026] Another characteristic of the formulation subject to invention is that its pH is between 4.5- 6.5, preferably between 5-6. This pH value is very close to pH 5.5 which is the skin pH.
[0027] Sample production steps are stated below:
[0028] Step 1 : Preparation of nanosuspension formulation
[0029] • As a suitable stabilizer, poloxamer is dissolved in water or dispersed in dispersion media,
[0030] • The active substance lidocaine is dispersed in this stabilizing solution and allowed to soak.
[0031] The prepared rough suspensions are pre-grinded with a high-speed homogenizer (Ultraturrax).
[0032] • The homogenization time and speed of the Ultraturrax method are optimized,
[0033] • The emerging dispersion is put into the chamber of the ball milling device,
[0034] • The appropriate size and number of balls are placed in the chamber.
[0035] • Optimization of the grinding time, speed, ball volume and size parameters of the ball milling method is provided.
[0036] • By adjusting the rotation speed and time, the device is operated and nanosuspensions are prepared,
[0037] • The prepared nanosuspensions are lyophilized.
[0038] Step 2: Preparation of thermosensitive gel formulation
[0039] • Poloxamer is dissolved in distilled water in an ice bath,
[0040] • Chitosan is added.
[0041] Step 3: Preparation of the final gel system
[0042] • Dexketoprofen trometamol is dissolved in a thermosensitive gel system,
[0043] • Lyophilized lidocaine nanosuspension is also added to the thermosensitive gel system and the final gel formulation is prepared.
[0044] The optimum nanosuspension and thermosensitive gel formulation developed is stated below. Lidocaine Nanosuspension Stabilized with Poloxamer
[0045] Lidocaine base . (2-10%)
[0046] Poloxamer . (%0.2-5)
[0047] Distilled water . qs . 100g
[0048] Final gel formulation
[0049] Lidocaine nanosuspension . (equivalent to 2-10% lidocaine)
[0050] Dexketoprofen trometamol . %1 ,85
[0051] Poloxamer . (%14-20)
[0052] Chitosan . (%0, 0625-1 )
[0053] Distilled water (comprising 0.5% acetic acid)...qs... 100g
[0054] Characterization studies were carried out separately for nanosuspensions and gel formulations.
[0055] Characterization studies performed for nanosuspensions:
[0056] • Particle size, polydispersity index and zeta potential determination
[0057] • Detection of morphological features (SEM)
[0058] • DSC, FTIR and XRD analysis
[0059] • Resolution Study
[0060] • In vitro release and ex vivo skin permeation studies, amounts of active substance remaining in the skin
[0061] • Physical and chemical stability studies
[0062] Characterization studies conducted on final gel formulations comprising nanosuspensions
[0063] • Assessment of physical appearance
[0064] • Particle size of the nanosuspension it carries
[0065] • pH determination
[0066] • Determination of gelation temperature and gelation time
[0067] • Viscosity determination
[0068] • Determination of rheological properties
[0069] • Texture profile analysis
[0070] • In vitro release and ex vivo skin permeation studies, the amount of active substance remaining in the skin. While developing the thermosensitive gel formulation, formulations were prepared with polyacrylate, hyaluronic acid and chitosan as gel agents, considering the ability to gel as soon as possible at 32 °C and characterization studies were carried out. As a result of the studies, the most suitable formulation was selected, and stability studies were carried out.
[0071] The findings regarding the evaluation of the physical and chemical stability of the final heat sensitive gel formulation are included in Tables 1 -4.
[0072] Table 1 . pH values of gel formulation measured at 4°C, 25°C and 40°C (n=3 m ean±S D )
[0073] Table 2. Viscosity values (n=3, mean±SD) of gel formulation measured at 50 rpm (Shear rate: 100sec’1) at 4°C, 25°C and 40°C
[0074] Table 3. Lidocaine contents of gel formulation measured at 4°C, 25°C and 40°C (n=3, mean±SD)
[0075] Table 4. Dexketoprofen contents of gel formulation measured at 4°C, 25°C and 40°C (n=3, mean±SD)
[0076] Explanation of the Figures
[0077] Figure 1 . Amounts of lidocaine remaining in the skin after ex vivo permeation study (n=3,*p<0.05)
[0078] A = Rough suspension prepared with polyvinylalcohol
[0079] B = Rough suspension prepared with poloxamer
[0080] C = Nanosuspension prepared with polyvinylalcohol B = Nanosuspension prepared with poloxamer
[0081] Advantages of the Invention
[0082] Thanks to the invention, a gel system with anti-inflammatory and local anesthetic effect has been developed which can be used topically in cases of radiodermatitis, that can be easily applied to the damaged skin area since it is liquid at room temperature, that instantly gels on the skin surface at body temperature to cover the damaged skin surface and that minimize the symptoms of radiodermatitis. This formulation will have a characteristic to be able to be used in the treatment of radiodermatitis due to the local pharmacological effect of the active substances it comprises, as well as the ease of use and instant gelation feature on the skin.
[0083] Thanks to the invention, a topical product has been developed that ensures suppression or relief of the local inflammatory response and pain sensation that develops in the skin with radiation therapy and that can be used easily by the patient. For easy application, it is intended that the developed drug form would have a sprayable / drippable viscosity and bear the characteristic of instant gelation on the skin surface after application. With this application, it will be possible for the patient or caregiver to apply the drug with minimal pain without touching the radiodermatitis area. Radiodermatitis caused by radiation therapy results in reduction of the radiation dose given to patients and sometimes discontinuation of the treatment. This leads to undesirable conditions in patients who are already facing a serious diagnosis and a doubtful prognosis.
[0084] With the invention, a new formulation has been developed to reduce the symptoms of radiation-induced dermatitis and an effective product has been obtained. The fact that the developed formulation comprises two active substances in combination and combines the advantages of nanosuspension and thermosensitive gel systems increases the antiinflammatory and analgesic efficacy. Thus, a more effective and easier-to-use product has been obtained.
[0085] This formulation to be used for the treatment of radiodermatitis is intended to be used especially in cancer patients receiving radiotherapy. Thus, the quality of life of the patients will be improved and radiation therapy will be able to continue without interruption due to radiodermatitis e.
[0086] Application of the Invention to Industry
[0087] Dexketoprofen and lidocaine nanosuspension is used for dermal administration once it has been prepared in a sprayable package with a suitable thermosensitive gel formulation.
Claims
CLAIMS1. A thermosensitive gel formulation characterized in that; a) Dexketoprofen trometamol as an anti-inflammatory, b) lidocaine nanosuspension as a local anesthetic, c) poloxamer as stabilizer for lidocaine nanosuspension, d) poloxamer and chitosan as gel agents.2 Gel formulation according to claim 1 , wherein lidocaine nanosuspension comprises lidocaine between 2-10% by weight.3 Gel formulation according to claim 1 , wherein lidocaine nanosuspension comprises 0.2-5% poloxamer by weight as a stabilizer.4 Gel formulation according to claim 1 , comprising 1 .5 - 2%, preferably 1 .85% dexketoprofen trometamol by weight.5 Gel formulation according to claim 1 , comprising 14-20% poloxamer by weight.6 Gel formulation according to claim 1 , comprising 0.0625-1 % chitosan by weight.7 Gel formulation according to claim 1 , wherein the lidocaine nanosuspension has the following composition:Lidocaine . (2-10%)Poloxamer . (0.2-5%)Distilled water . qs . 100g8 Gel formulation according to claim 1 , having the following composition:Lidocaine nanosuspension . (equivalent to 2-10% lidocaine)Dexketoprofen trometamol . 1 ,85%Poloxamer . (14-20%)Chitosan . (0,0625-1 %)Distilled water (containing 0.5% acetic acid)...qs.. ,100g9 Gel formulation according to claim 1 or claim 8, characterized in that its pH is between 4.5-6.5, preferably between 5-6.10 Gel formulation according to claim 1 for use in the treatment of radiodermatitis.
Citation Information
Patent Citations
Treatment for cellulitis and pre-operative treatment
US20220202825A1
